行情

MYOK

MYOK

MyoKardia
NASDAQ

实时行情|Nasdaq Last Sale

73.74
-1.44
-1.92%
盘后: 73.74 0 0.00% 17:10 01/17 EST
开盘
76.00
昨收
75.18
最高
76.56
最低
73.65
成交量
32.81万
成交额
--
52周最高
78.28
52周最低
39.01
市值
34.09亿
市盈率(TTM)
-14.1348
分时
5日
1月
3月
1年
5年

分析师评级

11位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MYOK 新闻

  • 去年中国吸收外资1400亿美元 仍是第二大外资流入国
  • 新华社.4小时前
  • 人脸识别技术该不该禁止?谷歌与微软各执一词
  • 新浪科技.4小时前
  • 隔夜要闻:美股周一休市 财报季进入白热化阶段在即
  • 新浪美股.6小时前
  • 供应充足预期冲淡利比亚局势影响 油价微涨
  • 新浪美股.6小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

MYOK 简况

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics. The Company has used its precision medicine platform to generate an initial pipeline of over four therapeutic programs for the chronic treatment of two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Additionally, the Company has three preclinical programs, HCM-2, DCM-2 and LUS-1. Its lead product candidate, MYK-461, is an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to HCM.
展开

Webull提供Myokardia Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。